Covered recipient · General Payments record
KATHARINE THOMAS
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$52,530.76
143 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for serving as faculty or as a speaker for a medical education program | $17,750.00 | 6 |
| Travel and Lodging | $16,425.34 | 51 |
| Consulting Fee | $12,252.00 | 3 |
| Food and Beverage | $3,603.42 | 82 |
| Honoraria | $2,500.00 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Exelixis Inc. | $47,731.09 | 90 |
| Novartis Pharmaceuticals Corporation | $1,650.00 | 1 |
| Daiichi Sankyo Inc. | $1,262.40 | 11 |
| AstraZeneca Pharmaceuticals LP | $280.55 | 9 |
| GENZYME CORPORATION | $273.23 | 2 |
| Novocure Inc. | $167.83 | 2 |
| Regeneron Healthcare Solutions, Inc. | $163.06 | 2 |
| Adaptive Biotechnologies Corporation | $160.33 | 2 |
| Deciphera Pharmaceuticals Inc. | $154.37 | 1 |
| Incyte Corporation | $105.40 | 4 |
| Astellas Pharma US Inc | $78.57 | 1 |
| ARRAY BIOPHARMA INC | $57.63 | 2 |
| Astellas Pharma Global Development | $56.38 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $43.56 | 2 |
| E.R. Squibb & Sons, L.L.C. | $42.76 | 1 |
| Janssen Biotech, Inc. | $42.25 | 2 |
| SpringWorks Therapeutics, Inc. | $42.06 | 1 |
| ADC THERAPEUTICS AMERICA, INC. | $34.88 | 1 |
| ABBVIE INC. | $31.84 | 1 |
| Kite Pharma, Inc. | $26.68 | 1 |
| Genmab U.S., Inc. | $25.27 | 1 |
| Legend Biotech USA Inc. | $23.27 | 1 |
| Ipsen Biopharmaceuticals, Inc | $22.31 | 1 |
| Iovance Biotherapeutics, Inc. | $20.98 | 1 |
| BeOne Medicines USA, Inc. | $18.71 | 1 |
| Lilly USA, LLC | $15.35 | 1 |
Page 2 of 3; records 51–100 of 143 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KATHARINE THOMAS
NPI 1588010482 · CMS profile ID 11305927
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
RENO, NV
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 143 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1588010482?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KATHARINE THOMAS, NPI 1588010482, CMS profile ID 11305927. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 143 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588010482?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). KATHARINE THOMAS, NPI 1588010482, CMS profile ID 11305927. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 143 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588010482?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- KATHARINE THOMAS, NPI 1588010482, CMS profile ID 11305927, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 143 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1588010482?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
143 matching records · $52,530.76 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 143.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Exelixis Inc. | $30.00 | 06/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797159 | CMS |
| Exelixis Inc. | $70.00 | 06/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797181 | CMS |
| Exelixis Inc. | $70.00 | 06/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797113 | CMS |
| Exelixis Inc. | $70.00 | 06/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797115 | CMS |
| Exelixis Inc. | $30.00 | 06/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797163 | CMS |
| Exelixis Inc. | $114.37 | 06/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797175 | CMS |
| AstraZeneca Pharmaceuticals LP | $99.86 | 06/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206141064 | CMS |
| Novartis Pharmaceuticals Corporation | $1,650.00 | 06/17/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200482199 | CMS |
| Regeneron Healthcare Solutions, Inc. | $38.07 | 06/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213057874 | CMS |
| Daiichi Sankyo Inc. | $13.30 | 06/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197100601 | CMS |
| ABBVIE INC. | $31.84 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204518058 | CMS |
| Exelixis Inc. | $4,500.00 | 06/11/2025 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797065 | CMS |
| Exelixis Inc. | $3,500.00 | 06/11/2025 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797095 | CMS |
| Exelixis Inc. | $340.38 | 06/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797127 | CMS |
| Exelixis Inc. | $3,586.55 | 06/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797129 | CMS |
| Exelixis Inc. | $124.80 | 06/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797143 | CMS |
| Exelixis Inc. | $2,053.04 | 06/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797155 | CMS |
| Exelixis Inc. | $572.47 | 06/04/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797079 | CMS |
| Astellas Pharma Global Development | $56.38 | 06/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234126714 | CMS |
| E.R. Squibb & Sons, L.L.C. | $42.76 | 06/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184718243 | CMS |
| Exelixis Inc. | $20.91 | 06/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797051 | CMS |
| Exelixis Inc. | $11.99 | 06/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797055 | CMS |
| Exelixis Inc. | $41.38 | 06/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797057 | CMS |
| Exelixis Inc. | $44.00 | 06/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797061 | CMS |
| Exelixis Inc. | $8.00 | 06/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797063 | CMS |
| Exelixis Inc. | $3.91 | 06/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797071 | CMS |
| Exelixis Inc. | $36.52 | 06/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797073 | CMS |
| Exelixis Inc. | $4.49 | 06/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797075 | CMS |
| Exelixis Inc. | $11.35 | 06/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797077 | CMS |
| Exelixis Inc. | $8.00 | 06/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797087 | CMS |
| Exelixis Inc. | $302.01 | 06/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797097 | CMS |
| GENZYME CORPORATION | $108.36 | 05/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233217912 | CMS |
| Deciphera Pharmaceuticals Inc. | $154.37 | 05/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235961623 | CMS |
| Exelixis Inc. | $38.51 | 05/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797105 | CMS |
| Genmab U.S., Inc. | $25.27 | 05/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235921314 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $24.11 | 05/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223890149 | CMS |
| Exelixis Inc. | $208.56 | 05/21/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797101 | CMS |
| Exelixis Inc. | $30.00 | 05/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797069 | CMS |
| Exelixis Inc. | $125.00 | 05/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797083 | CMS |
| Exelixis Inc. | $70.00 | 05/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797085 | CMS |
| Novocure Inc. | $13.92 | 05/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251148851 | CMS |
| Exelixis Inc. | $2,500.00 | 05/15/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797041 | CMS |
| Daiichi Sankyo Inc. | $13.30 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197064311 | CMS |
| Ipsen Biopharmaceuticals, Inc | $22.31 | 05/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208856511 | CMS |
| Exelixis Inc. | $70.00 | 05/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797053 | CMS |
| Exelixis Inc. | $30.00 | 05/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797067 | CMS |
| Exelixis Inc. | $70.00 | 05/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797081 | CMS |
| Exelixis Inc. | $117.17 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218797099 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.66 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206926547 | CMS |
| Lilly USA, LLC | $15.35 | 05/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186702813 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $728,618.15 | 13 |
| PY2024 | Principal investigator | $46,300.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
13 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $269,708.82 | 12/31/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A Randomized, Open label, Phase 3 Study of MK-2870 in Combination with Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer with PD-L1 TPS Greater Than or Equal To 50 | No dispute reported | 06/30/2026 | 1232923312 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $285,450.17 | 12/31/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Follow | No dispute reported | 06/30/2026 | 1232924036 |
| Principal investigator 1 | Janssen Research & Development, LLC | $650.00 | 11/03/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib | No dispute reported | 06/30/2026 | 1175427349 |
| Principal investigator 1 | ABBVIE INC. | $8,500.00 | 09/10/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1202419153 |
| Principal investigator 1 | ABBVIE INC. | $18,384.00 | 09/04/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1202419149 |
| Principal investigator 1 | ABBVIE INC. | $8,500.00 | 07/14/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202419145 |
| Principal investigator 1 | Genentech, Inc. | $350.00 | 07/01/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | No dispute reported | 06/30/2026 | 1211553310 |
| Principal investigator 1 | ABBVIE INC. | $18,384.00 | 06/03/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202419141 |
| Principal investigator 1 | Genentech, Inc. | $900.00 | 05/23/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | No dispute reported | 06/30/2026 | 1211553313 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,868.16 | 04/23/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% | No dispute reported | 06/30/2026 | 1236000340 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 04/22/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | No dispute reported | 06/30/2026 | 1211553326 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 04/07/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | No dispute reported | 06/30/2026 | 1211553322 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $114,923.00 | 02/06/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% | No dispute reported | 06/30/2026 | 1236000338 |